| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| OpGen Inc. | BV100 | Infections caused by Carbapenem Resistant Acinetobacter baumannii (CRAB) | Phase 2 | Intravenous | Antibiotic | |
| Opko Health Inc. | OPK88004 | Benign Prostatic Hyperplasia (BPH) | Phase 2b | Trial Completed | Oral | N/A |
| Opko Health Inc. | OPK88003 | Obesity and diabetes | Phase 2b | Trial Completed | Subcutaneous | Endocrinology |
| Opko Health Inc. | RAYALDEE - (REsCue) | Mild-to-moderate COVID-19 | Phase 2 | Ongoing | Oral | COVID-19 |
| Opko Health Inc. | RAYALDEE | Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) - Stage 5 | Phase 2 | Data Released | oral | Endocrinology |
| Opthea Limited | Sozinibercept (OPT-302) with Aflibercept - (COAST) | Age-related macular degeneration (AMD) | Phase 3 | Trial Discontinued | Intravitreal injection | Opthalmic |
| Opthea Limited | Sozinibercept (OPT-302) with Ranibizumab - (ShORe) | Wet age-related macular degeneration (AMD) | Phase 3 | Trial Discontinued | Intravitreal injection | Opthalmic |
| OptiNose Inc. | XHANCE - (ReOpen2) | Chronic sinusitis | Phase 3 | Ongoing | Intranasal | Respiratory |